Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription 08.12.2025 1 AJR Am J Roentgenol 1 Am J Surg 2 Ann Surg Oncol 6 Anticancer Res 9 BMC Cancer 2 BMJ 1 Breast Cancer 4 Breast Cancer (Auckl) 3 Breast Cancer (Dove Med Press) 3 Breast Cancer Res 2 Breast Cancer Res Treat 1 Breast J 1 Cancer 1 Cancer Chemother Pharmacol 3 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 2 Cancer Res 1 Clin Breast Cancer 5 Clin Cancer Res 1 Clin Med Insights Oncol 1 Eur J Surg Oncol 1 J Clin Invest 5 NPJ Breast Cancer 4 PLoS One 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. BAHL M, Kim K, Kim H, Alkhadrawi A, et al
   Commercial Artificial Intelligence (AI) Tool for Screening Digital Breast Tomosynthesis: Factors Associated With AI-Based Breast Cancer Detection.
   AJR Am J Roentgenol. 2025 Dec 3. doi: 10.2214/AJR.25.33792.
   PubMed        
   
   

   
   Am J Surg

2. DEN J, Baughn C, Klimberg VS
   Is anastrozole really better than tamoxifen for low-risk breast cancer?
   Am J Surg. 2025;252:116734.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. PARMAR P, Lin J, Bhimani F, Jao L, et al
   Zip-Code Level Disadvantage as a Predictor of Metastatic Breast Cancer at Diagnosis and Delayed Treatment Initiation.
   Ann Surg Oncol. 2025 Dec 1. doi: 10.1245/s10434-025-18693.
   PubMed         Abstract available
   
   
4. TSUCHIDA J, Wu R, Nagahashi M, Ebos JML, et al
   ASO Author Reflections: DNA Repair and Tumor Immunity in Breast Cancer: A Context-Dependent Role for TRIM37.
   Ann Surg Oncol. 2025 Dec 2. doi: 10.1245/s10434-025-18852.
   PubMed        
   
   

   
   Anticancer Res

5. KIM HB, Kim SH, Lee HJ, Park SG, et al
   Down-regulation of ACSM3 Promotes Tumorigenesis in Breast Cancer.
   Anticancer Res. 2025;45:5435-5443.
   PubMed         Abstract available
   
   
6. USUI T, Shimoda M, Abe K, Masunaga N, et al
   Effect of Tissue Sample Type on The Evaluation of PD-L1 (SP142) Expression in Breast Cancer.
   Anticancer Res. 2025;45:5587-5594.
   PubMed         Abstract available
   
   
7. KOI Y, Tajiri W, Kawasaki J, Akiyoshi S, et al
   Efficacy and Safety of Oral 5-FU Derivatives After Progression of HR(+)/HER2(-) Metastatic Breast Cancer on CDK4/6 Inhibitor.
   Anticancer Res. 2025;45:5609-5618.
   PubMed         Abstract available
   
   
8. MAHMOOD S, Chernov AV, Khan S, Chitteti R, et al
   NSUN7 Suppression Reduces Metastatic Potential and Restores Sensitivity to 4-OH Tamoxifen in Resistant MCF-7 Cells.
   Anticancer Res. 2025;45:5321-5339.
   PubMed         Abstract available
   
   
9. JANG YS, Jeon SJ, Lee SW, Lee SA, et al
   Piperlongumine Induces Apoptosis and Autophagy via the MAPK/NK-kappaB Pathway in Human Breast Cancer Cells.
   Anticancer Res. 2025;45:5423-5434.
   PubMed         Abstract available
   
   
10. ADMANEGARA PPS, Yulianti R, Rahmawati D, Widiastuti S, et al
    Leveraging Genome-wide Association Studies to Identify Pathogenic Variants for Breast Cancer Among Multiple Continents.
    Anticancer Res. 2025;45:5351-5367.
    PubMed         Abstract available
    
    

    
    BMC Cancer

11. BAS O, Inci BK, Eroglu I, Efil SC, et al
    Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience.
    BMC Cancer. 2025;25:1831.
    PubMed         Abstract available
    
    
12. HAFEEZ A, Basit M, Zafar S, Shabbir M, et al
    Comprehensive analysis of gene expression alterations in breast cancer patients via PKCtheta-TBK1-mTORC1 signaling pathway.
    BMC Cancer. 2025;25:1844.
    PubMed         Abstract available
    
    
13. RANTALA J, Seppa K, Eriksson J, Heinavaara S, et al
    Associations between modifiable factors and early-onset breast cancer mortality among patients.
    BMC Cancer. 2025 Nov 29. doi: 10.1186/s12885-025-15226.
    PubMed         Abstract available
    
    
14. TAKADA K, Kashiwagi S, Nishikawa M, Kochi A, et al
    Clinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs).
    BMC Cancer. 2025 Nov 28. doi: 10.1186/s12885-025-15255.
    PubMed         Abstract available
    
    
15. LIU C, Wang R, Wang S, Liu S, et al
    Pregnancy-associated breast cancer: gestational weight gain impact and nomogram validation.
    BMC Cancer. 2025 Nov 29. doi: 10.1186/s12885-025-15292.
    PubMed         Abstract available
    
    
16. PETER J, Jolly B, Raha R, Jothi J, et al
    Germline mutational landscape in a large cohort of Indian breast cancer.
    BMC Cancer. 2025 Dec 1. doi: 10.1186/s12885-025-15360.
    PubMed        
    
    
17. DU R, Qian R, Qin R, Yu Y, et al
    Gradient perfusion features can effectively identify sentinel lymph node metastasis in early breast cancer.
    BMC Cancer. 2025 Dec 1. doi: 10.1186/s12885-025-15251.
    PubMed        
    
    
18. JENKINSON NM, Hughes S, Baras A, Meeker A, et al
    Context-dependent MAN1A1 protein expression in metastatic breast cancer progression predicts patient survival.
    BMC Cancer. 2025 Dec 1. doi: 10.1186/s12885-025-15380.
    PubMed         Abstract available
    
    
19. SARFRAZ Z, Ozair A, Bardhan M, Starosciak AK, et al
    Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15224.
    PubMed         Abstract available
    
    

    
    BMJ

20. NICKEL B, Ormiston-Smith N, Cvejic E, Isautier J, et al
    Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.
    BMJ. 2025;391:e083649.
    PubMed         Abstract available
    
    
21. DYER C
    Breast cancer failings: "Culture of complacency" led to unnecessary surgery and delayed treatment at NHS trust.
    BMJ. 2025;391:r2527.
    PubMed        
    
    

    
    Breast Cancer

22. NAIMI Z, Riahi A, Slim A, Ben Amor R, et al
    Two breasts, one breath: continuous positive airway pressure for innovative heart sparing in synchronous bilateral breast cancer radiotherapy.
    Breast Cancer. 2025 Dec 4. doi: 10.1007/s12282-025-01807.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

23. GHAFOURI-ASBAGH A, Tabatabaei K, Vaez H, Jafarizadeh A, et al
    Memantine, an NMDA Receptor Antagonist, Attenuates Doxorubicin-Induced Cardiac Oxidative Stress and Inflammation in Mouse 4T1 Breast Cancer Model.
    Breast Cancer (Auckl). 2025;19:11782234251393421.
    PubMed         Abstract available
    
    
24. OKECHA T, Yahaya JJ, Waiswa A, Nyakato V, et al
    Ki67 Expression and Its Association With Clinicopathological Factors and Intrinsic Subtypes of Male Breast Cancer in Uganda: A Cross-sectional Study.
    Breast Cancer (Auckl). 2025;19:11782234251392693.
    PubMed         Abstract available
    
    
25. SALAMOON M, Ahmad H, Ktyman H, Chaker D, et al
    Total Body PET/MRI as a Gold Standard for Staging Breast Cancer During Pregnancy in a Case Report.
    Breast Cancer (Auckl). 2025;19:11782234251396398.
    PubMed         Abstract available
    
    
26. GAMBARO K, Rachedi K, Basik M, Saad F, et al
    Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting.
    Breast Cancer (Auckl). 2025;19:11782234251395892.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

27. CHEN X, Lan X, Xiao L, Song L, et al
    Delayed Cardiac Dysfunction During Prolonged Use of Trastuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer.
    Breast Cancer (Dove Med Press). 2025;17:1101-1110.
    PubMed         Abstract available
    
    
28. YU Z, Ma W, Zhang Y, Gao Y, et al
    Advances in DCE-MRI Radiomics for Non-Invasive Prediction of Breast Cancer Molecular Subtypes: Research Progress and Clinical Translation.
    Breast Cancer (Dove Med Press). 2025;17:1111-1118.
    PubMed         Abstract available
    
    
29. LI YF, Yuan Y, Chen C, Zhu ML, et al
    Comprehensive Analysis and Experimental Validation of Single-Cell and Transcriptome Sequencing Reveal SGO2 as a Novel Biomarker for Breast Cancer.
    Breast Cancer (Dove Med Press). 2025;17:1083-1100.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

30. DEVAUX A, Beniuga G, Delree P, Quaghebeur C, et al
    Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer.
    Breast Cancer Res. 2025;27:212.
    PubMed         Abstract available
    
    
31. STEEN S, Karlsson E, Bjornheden I, Rask G, et al
    Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study.
    Breast Cancer Res. 2025;27:213.
    PubMed         Abstract available
    
    
32. CHATSATOURIAN C, Lo Faro V, Karlsson T, Hadizadeh F, et al
    Breast cancer risk during oral contraceptive use in women with high polygenic risk.
    Breast Cancer Res. 2025 Dec 1. doi: 10.1186/s13058-025-02177.
    PubMed        
    
    

    
    Breast Cancer Res Treat

33. OGU JC, Ozcan BB, Dogan BE, Xi Y, et al
    Patient perspectives on artificial intelligence in mammography interpretation: a comparative survey study of safety-net and academic hospital settings.
    Breast Cancer Res Treat. 2025;215:25.
    PubMed         Abstract available
    
    
34. PATHAK N, Kimmel A, Berner-Wygoda Y, Almuthri SA, et al
    Using the cancer aging and research group- breast cancer (CARG-BC) predictive model in older adults (OA) with early breast cancer: an external validation study.
    Breast Cancer Res Treat. 2025;215:24.
    PubMed         Abstract available
    
    

    
    Breast J

35. ZHOU L, Wang X, Zhu H, Chen Y, et al
    GSK-3beta Regulates Tumor Stemness and Immune-Related Pathways in Triple-Negative Breast Cancer: A Bioinformatics and Experimental Validation Study.
    Breast J. 2025;2025:5943807.
    PubMed         Abstract available
    
    

    
    Cancer

36. LAWRENCE L
    Studies evaluate de-escalation of treatment for certain patients with breast cancer: No significant differences were found in overall survival rates between the group receiving chemotherapy plus hormonotherapy and the group receiving hormonotherapy al
    Cancer. 2025;131:e70135.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

37. CATALANO M, Cekrezi G, De Gennaro Aquino I, Ravizza D, et al
    Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer.
    Cancer Chemother Pharmacol. 2025;95:117.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

38. VAN ALSTEN SC, Love MI, Calhoun BC, Butler EN, et al
    Identifying locally recurrent versus second primary breast cancer: Genomic versus clinical criteria from Carolina Breast Cancer Study Phase III.
    Cancer Epidemiol Biomarkers Prev. 2025 Dec 1. doi: 10.1158/1055-9965.EPI-25-1298
    PubMed         Abstract available
    
    
39. CASTON NE, Spees LP, Waters AR, Wheeler SB, et al
    Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography.
    Cancer Epidemiol Biomarkers Prev. 2025;34:2150-2157.
    PubMed         Abstract available
    
    
40. MCVICKER L, Gunathilake KAMP, Cardwell CR, Kunzmann AT, et al
    Metabolic Syndrome and the Risk of Breast, Endometrial, and Ovarian Cancer among Postmenopausal Women in the UK Biobank.
    Cancer Epidemiol Biomarkers Prev. 2025;34:2125-2134.
    PubMed         Abstract available
    
    

    
    Cancer Lett

41. DUAN F, Zhang C, Wu Z, Zhuang L, et al
    Copper Orchestrates Triple-negative Breast Cancer Progression via the STEAP3-dependent CDK16-JAK1 Activation.
    Cancer Lett. 2025 Dec 1:218192. doi: 10.1016/j.canlet.2025.218192.
    PubMed         Abstract available
    
    

    
    Cancer Res

42. CHENG Y, Huang G, Liu X, Wu C, et al
    Fusion of Tumor Cells with Lipid-Associated Macrophages Drives Metastatic Progression of Breast Cancer.
    Cancer Res. 2025 Dec 4:OF1-OF18. doi: 10.1158/0008-5472.CAN-25-0261.
    PubMed         Abstract available
    
    
43. ARNOUK SM, Kancheva D, Van Damme H, Courtoy GE, et al
    Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti-PD-1 Immunotherapy.
    Cancer Res. 2025;85:4681-4700.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

44. AYDIN AA, Kayikcioglu E
    Beyond BMI: Metabolic and Inflammatory Determinants of Recurrence After Neoadjuvant Therapy in Breast Cancer.
    Clin Breast Cancer. 2025;26:47-48.
    PubMed        
    
    

    
    Clin Cancer Res

45. CIRUELOS E, Pascual T, Villacampa G, Pernas S, et al
    Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial.
    Clin Cancer Res. 2025 Dec 3. doi: 10.1158/1078-0432.CCR-25-2882.
    PubMed         Abstract available
    
    
46. LYNCE F, Graham N, Kochupurakkal BS, Nguyen H, et al
    A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer.
    Clin Cancer Res. 2025 Dec 3. doi: 10.1158/1078-0432.CCR-25-0571.
    PubMed         Abstract available
    
    
47. DAHMER TIECHER R, Schram AM
    Tumor-Agnostic AKT Inhibition: Is It Time to AKT?
    Clin Cancer Res. 2025;31:4863-4865.
    PubMed         Abstract available
    
    
48. CORTES J, Priego A, Garralda E, Rojas K, et al
    A First-in-Class mAb (BI-1607) Targeting FcgammaRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.
    Clin Cancer Res. 2025;31:4953-4963.
    PubMed         Abstract available
    
    
49. SANFELIU E, Martinez-Romero A, Marin-Aguilera M, Cobo S, et al
    Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer.
    Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-3123.
    PubMed         Abstract available
    
    

    
    Clin Med Insights Oncol

50. GAO Y, Li Z, Li Z, Gao X, et al
    Machine Learning-Based Enhanced MRI Radiomics for PDCD1 Prognostication and Expression Prediction in Breast Cancer.
    Clin Med Insights Oncol. 2025;19:11795549251399383.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

51. BARJOT C, Gaillard T, Seban RD, Darrigues L, et al
    Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery.
    Eur J Surg Oncol. 2025;51:110511.
    PubMed         Abstract available
    
    

    
    J Clin Invest

52. ARJONEN A, Kaukonen R, Mattila E, Rouhi P, et al
    Corrigendum to Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.
    J Clin Invest. 2025;135:e201379.
    PubMed        
    
    

    
    NPJ Breast Cancer

53. JACOB S, Fisch S, Face C, Blum K, et al
    Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer.
    NPJ Breast Cancer. 2025 Dec 3. doi: 10.1038/s41523-025-00849.
    PubMed         Abstract available
    
    
54. HOUSE NC, Chen MM, Khazaei S, Brown V, et al
    CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen.
    NPJ Breast Cancer. 2025;11:135.
    PubMed         Abstract available
    
    
55. PIZZAMIGLIO S, Blanda A, Appierto V, Minicozzi P, et al
    HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy.
    NPJ Breast Cancer. 2025 Dec 3. doi: 10.1038/s41523-025-00867.
    PubMed         Abstract available
    
    
56. WAN Y, Wang J, O'Connor TN, Kumarasamy V, et al
    Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer.
    NPJ Breast Cancer. 2025;11:134.
    PubMed         Abstract available
    
    
57. GIRIDHAR KV, Sinnwell JP, Slettedahl SW, Taylor WR, et al
    Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer.
    NPJ Breast Cancer. 2025 Nov 29. doi: 10.1038/s41523-025-00866.
    PubMed         Abstract available
    
    

    
    PLoS One

58. HOSSIN AY, Rahman MN, Hasan MM, Karim A, et al
    Evaluation of dihydropyranocoumarins as potent inhibitors against triple-negative breast cancer: An integrated of in silico, quantum & molecular modeling approaches.
    PLoS One. 2025;20:e0334939.
    PubMed         Abstract available
    
    
59. ALSALAH JH
    Incidental extramammary findings on breast magnetic resonance imaging: Prevalence and recommended diagnostic follow-up.
    PLoS One. 2025;20:e0319373.
    PubMed         Abstract available
    
    
60. ZHAO Y, Lan S, Li X, Deng Y, et al
    Investigating the mechanism of oridonin against triple-negative breast cancer based on network pharmacology and molecular docking.
    PLoS One. 2025;20:e0332697.
    PubMed         Abstract available
    
    
61. LIANG B, Duan Z, Long S, Zhou P, et al
    Infiltration of CXCL9+ macrophages confers a favorable prognosis in breast cancer: Insights from an integrated single-cell RNA and bulk RNA sequencing study.
    PLoS One. 2025;20:e0337175.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

62. NG S, Kirby AM, Kilburn LS, Griffin C, et al
    Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5?years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials.
    Radiother Oncol. 2025 Nov 27:111301. doi: 10.1016/j.radonc.2025.111301.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.